MedTrace Logo

Immunodeficiency in MS

NCT04447937 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2020-06-25

No results posted yet for this study

Summary

The purpose of this study is to identify if there is a relationship between multiple sclerosis disease-modifying therapy exposure, immunodeficiencies, and infection risk in subjects living with MS.

Conditions

Interventions

OTHER

No Interventions

There are no interventions associated with the study.

Sponsors & Collaborators

  • Novel Pharmaceutics Institute

    collaborator UNKNOWN

  • Advanced Neurosciences Institute

    lead OTHER

Principal Investigators

  • Samuel F Hunter, MD, PhD · Advanced Neurosciences Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2021-01-30
Completion
2021-07-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04447937 on ClinicalTrials.gov